Ronald Peck - 30 Jun 2021 Form 4 Insider Report for ARVINAS, INC. (ARVN)

Role
Chief Medical Officer
Signature
/s/ Matthew Batters, as attorney-in-fact for Ronald Peck
Issuer symbol
ARVN
Transactions as of
30 Jun 2021
Net transactions value
-$586,200
Form type
4
Filing time
02 Jul 2021, 20:00:31 UTC
Next filing
16 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARVN Common Stock Options Exercise $947,600 +20,000 +726% $47.38 22,754 30 Jun 2021 Direct F1
transaction ARVN Common Stock Sale $1,533,800 -20,000 -88% $76.69 2,754 30 Jun 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARVN Stock Option (right to buy) Options Exercise $0 -20,000 -27% $0.000000 55,000 30 Jun 2021 Common Stock 20,000 $47.38 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.
F2 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.20 to $77.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range set forth in this footnote (3).
F4 This option award was granted on February 27, 2020, 1/4 of the shares underlying the award shall vest on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.